Upregulation of Trop-2 quantitatively stimulates human cancer growth. - Wikidata - awgldk - TriplyDB

Upregulation of Trop-2 quantitatively stimulates human cancer growth.

Upregulation of Trop-2 quantitatively stimulates human cancer growth.

http://www.wikidata.org/entity/Q39393545

about

Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications Trop-2 is a determinant of breast cancer survival Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Trop-2 promotes prostate cancer metastasis by modulating β(1) integrin functions.Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways.Epigenetic heredity of human height.Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma.mTrop1/Epcam knockout mice develop congenital tufting enteropathy through dysregulation of intestinal E-cadherin/β-catenin.Long-range transcriptome sequencing reveals cancer cell growth regulatory chimeric mRNA.Overexpression of EpCAM and Trop2 in pituitary adenomas Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway.A unique four-hub protein cluster associates to glioblastoma progression.Pten Regulates Epithelial Cytodifferentiation during Prostate Development.First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors Systems-level effects of ectopic galectin-7 reconstitution in cervical cancer and its microenvironment.Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).A multi-layer inference approach to reconstruct condition-specific genes and their regulation.Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis Trop2: from development to disease.Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.Molecular targets and pathways involved in liver metastasis of colorectal cancer.Sacituzumab govitecan: an antibody-drug conjugate.Trop2 inhibition suppresses the proliferation and invasion of laryngeal carcinoma cells via the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway.Trop2 gene: a novel target for cervical cancer treatment.Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.The Trop-2 signalling network in cancer growth.Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation.Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas.A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.Trop2 regulates motility and lamellipodia formation in cultured fetal lung fibroblasts.New agents for the management of resistant metastatic breast cancer.Clinical Value of Serum Trophoblast Cell Surface Protein 2 (TROP2) Antibody in Non-small Cell Lung Cancer Patients.TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells.The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.

P2860

Q27004380-1D8EB1B1-3E64-4BD3-8CC5-0C54D03CE724 Q27333611-2893C59D-02A9-476A-9C76-512B68616538 Q28586334-58B02199-F9C0-4760-9BCA-E768D499B3CA Q30101057-D30C6449-9240-46F6-8455-F1E8E0E8C0B0 Q30539832-A590D57F-F405-4FC6-BA20-B8D0C24D763F Q33909333-A121ADB4-7CB5-400B-B314-8567732E6D7B Q34399991-73F0BD9F-DF2E-4B79-91CF-92D96367AE38 Q34476583-C781765E-B316-48E9-9BD8-B9416F61D356 Q34499625-EF88E7EE-825D-4AFE-9B87-DC09287F1E3B Q34504867-847A208D-6968-4582-919D-CED021BB767E Q34733193-DEAEED42-5D8F-44D4-AAD8-322C58A066E6 Q35006035-11E0E3D5-83F2-45FE-8FC4-48AD0E36B1BC Q35210961-08F75FE3-1D1C-4DA5-AC8B-B65F1FF47671 Q35664021-E5CE5AAC-10BC-4C58-8FF2-7E6A9E908D83 Q36021635-EFEF8136-282F-443B-ABB4-8444467D3609 Q36112218-B61C47B9-570B-4F9A-BA17-1779D65886DC Q36356001-3FDEFCAB-AC8B-4F6F-9101-7BB20D640233 Q36904403-6BAA1E29-3D65-4AA1-9298-3FA260E50502 Q37267470-8CBA9237-6986-4A56-AFB6-1FAFBD7435EC Q38293559-D9092630-7B67-4304-AE54-D2BF8C875CEC Q38375607-C9D308BC-3848-4F34-B6BE-4A3C6FCEA0CD Q38535666-10E3A15B-FA1B-4517-85A1-6AC6244AB354 Q38683957-ECC1664F-7F7E-4EDB-80FF-5CFF6956786E Q38898634-7F369544-C803-45DE-8D6D-8D1878EB2936 Q38996163-EE7AF2D6-ED75-47F9-AA10-1649AD6176E9 Q39388098-E279E78C-54EA-4F27-88B3-B40544B0BB45 Q41709315-27E3690F-9A92-4905-B82C-56CF5A5990F5 Q42747405-AB68989E-9A3F-4684-AEFC-A4D50401205A Q45826058-8E1D5514-6337-47DD-99FE-8AC04FF419B3 Q46450905-2005EBB6-36E3-408A-BDF8-C4EB06C745B7 Q47109220-72C91666-9AB8-45F0-91C8-D57EE6D6C38C Q47147021-0FAAE493-280B-4C0D-87CE-9BE48D38F918 Q47732625-C04B727B-C905-4C38-9DAA-B5268901662E Q47851750-939E267F-7433-48E4-8AB6-10B053017550 Q47917074-FAA5C441-5DDD-43D8-BEE0-23B30123B758 Q48240854-D9246546-6723-422C-83AC-40F7542866A5 Q51699828-B1090587-6A65-4DE1-A4F2-65C336F6AE02 Q53306473-336E28AA-8E68-4CE3-8995-D8EF75E33F66 Q55380170-FB59FB5B-658C-439B-B6E6-9B9127AFB179 Q55508847-DD0698FC-6CB0-4A80-9B2B-1A2196A57581

P2860

Upregulation of Trop-2 quantitatively stimulates human cancer growth.

http://www.wikidata.org/entity/Q39393545

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Upregulation of Trop-2 quantitatively stimulates human cancer growth.

@en

Upregulation of Trop-2 quantitatively stimulates human cancer growth.

@nl

type

label

Upregulation of Trop-2 quantitatively stimulates human cancer growth.

@en

Upregulation of Trop-2 quantitatively stimulates human cancer growth.

@nl

prefLabel

Upregulation of Trop-2 quantitatively stimulates human cancer growth.

@en

Upregulation of Trop-2 quantitatively stimulates human cancer growth.

@nl

P1433

Q39393545-D6CCF733-CCE2-46A2-919B-13516DD6C181

P1476

Q39393545-76A62668-2638-4D65-A0E5-85F2F6F9D05D

P2093

Q39393545-23EBD75A-8001-48E6-9588-2D31AEC93AF6

Q39393545-4329B9B8-9FAC-4436-8612-3B03C496A0AF

Q39393545-67F77A3E-333B-4639-A04C-0D477CF82790

Q39393545-6A5C1EB8-E5A7-44FD-B9F4-91358F3DA07E

Q39393545-80676F9D-DEA6-45B1-91B4-4D5F2BECFC58

Q39393545-A910D3A8-4843-476F-B710-046FE48BBF62

Q39393545-B0BD52F0-AB45-40B7-82DF-5C870A6873DF

Q39393545-BEE0EE1A-F5DA-403D-A821-DA925F86C5B2

Q39393545-E697E237-21C7-4914-8F6D-83DAE65530A4

Q39393545-FB49906B-5370-47C8-9B08-49A1349C5249

P2888

Q39393545-31596F09-853D-41F5-9C13-86A6F057C240

P304

Q39393545-62EA660E-2FEB-4307-A52B-5602ACC727F2

P31

Q39393545-C4181C3E-3219-440B-BE50-E8DDD3CB17D7

P356

Q39393545-7EABD609-6256-450D-BDEB-B07BD8015228

P407

Q39393545-9B07558A-BA8A-4853-A246-AEFDC502A021

P433

Q39393545-42C43536-71E8-4A2A-B12E-91B99168B0F9

P478

Q39393545-117B0AA8-576D-471D-80A2-A6586EB379E5

P50

Q39393545-0F071CE0-0074-4FBE-A56C-BA1B6AE2128D

P577

Q39393545-6A0E7647-3A2F-41FB-9F6C-0BE943A8D695

P5875

Q39393545-F7C4D7A7-7942-472C-854D-8A03F55715BD

P698

Q39393545-F059A2A0-80CE-42DE-BD00-B1EEB0BBEE3B

P356

P1433

P1476

Upregulation of Trop-2 quantitatively stimulates human cancer growth.

@en

P2093

A L Aloisi

http://www.w3.org/2001/XMLSchema#string

E Guerra

http://www.w3.org/2001/XMLSchema#string

M Trerotola

http://www.w3.org/2001/XMLSchema#string

P Cantanelli

http://www.w3.org/2001/XMLSchema#string

R Lattanzio

http://www.w3.org/2001/XMLSchema#string

R Tripaldi

http://www.w3.org/2001/XMLSchema#string

R de Lange

http://www.w3.org/2001/XMLSchema#string

S Alberti

http://www.w3.org/2001/XMLSchema#string

U H Weidle

http://www.w3.org/2001/XMLSchema#string

V Bonasera

http://www.w3.org/2001/XMLSchema#string

P2888

P304

222-233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2012.36

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Mauro Piantelli

P577

2012-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221847127

http://www.w3.org/2001/XMLSchema#string

P698

22349828

http://www.w3.org/2001/XMLSchema#string